ClinicalTrials.Veeva

Menu
R

Red Osmo | Centro de Investigacion Medica Aguascalientes

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Galcanezumab
Lasmiditan
LY573144
MK-8835-059
Estrogen
Giredestrant
Alectinib
Ertugliflozin
PF-04971729
LY3298176

Parent organization

This site is a part of Red Osmo

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 8 total trials

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of m...

Enrolling
Migraine
Drug: Lasmiditan

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling
Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib

Brigatinib is a medicine that binds to the surface of tumor cells in some cancers and delivers a dose of chemotherapy directly to the tumor. In this...

Active, not recruiting
ALK+ Advanced NSCLC
Drug: Brigatinib
Drug: Alectinib

The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participant...

Enrolling
Chronic Migraine
Drug: Placebo
Drug: Galcanezumab

The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatme...

Enrolling
Episodic Migraine
Drug: Galcanezumab
Drug: Placebo

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks an...

Enrolling
Migraine
Drug: Placebo
Drug: Lasmiditan

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide

This study will evaluate the safety and efficacy of ertugliflozin (MK-8835) in pediatric participants with T2DM on metformin with/without insulin. Th...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Metformin
Drug: Placebo to ertugliflozin 5 mg

Trial sponsors

Lilly logo
Merck Sharp & Dohme (MSD) logo
Roche logo
Takeda logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems